



October 22, 2019

British Columbia Securities Commission  
Alberta Securities Commission  
Financial and Consumer Affairs Authority of Saskatchewan  
Ontario Securities Commission

Dear Sirs/Mesdames:

**Re: Algernon Pharmaceuticals Inc.**

In connection with the amended and restated final short form prospectus of Algernon Pharmaceuticals Inc. dated October 22, 2019 (the "**Amended and Restated Final Prospectus**"), we consent to the references to our name on page iii and under the headings "Legal Matters" and "Interest of Experts" and consent to the use of our firm's name and reference to our opinion under the heading "Eligibility for Investment" in the Amended and Restated Final Prospectus.

We have read the Amended and Restated Final Prospectus and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from our opinion referred to therein or that are within our knowledge as a result of the services that we performed in connection with such opinion.

Yours truly,

(signed) "*McMillan LLP*"